Avila Alvarez A, García-Alonso L, Solar Boga A, García-Silva J
Servicio de Pediatría, Unidad de Gastroenterología Pediátrica, Complejo Hospitalario Universitario de A Coruña, A Coruña, España.
An Pediatr (Barc). 2009 Mar;70(3):278-81. doi: 10.1016/j.anpedi.2008.11.013. Epub 2009 Feb 8.
Anti-TNF drugs are used increasingly in several diseases with immune-mediated inflammation, not only in rheumatological conditions, but also in inflammatory bowel disease and psoriasis. Different side effects have been described over the last few years, including the development of psoriasis or psoriasiform exanthemas. These drugs began to be used in paediatrics during the 90's, therefore paediatricians need to be aware of the adverse effects that may occur. We describe here a flexural psoriasis induced by both infliximab and adalimumab in a paediatric patient with Crohn's Disease. To the best of our knowledge, this is the first reported paediatric case of psoriasis triggered by an anti-TNF drug, as well as the first case of psoriasis induced by adalimumab in patients with inflammatory bowel disease.
抗TNF药物越来越多地用于多种免疫介导炎症性疾病，不仅用于风湿性疾病，还用于炎症性肠病和银屑病。在过去几年中已描述了不同的副作用，包括银屑病或银屑病样皮疹的发生。这些药物在90年代开始用于儿科，因此儿科医生需要了解可能出现的不良反应。我们在此描述了一名患有克罗恩病的儿科患者中由英夫利昔单抗和阿达木单抗诱发的屈侧银屑病。据我们所知，这是首例报道的由抗TNF药物引发的儿科银屑病病例，也是炎症性肠病患者中首例由阿达木单抗诱发的银屑病病例。
